23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection

ABFM Family Medicine Certification Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making

1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care

2 Chapter 2: Healthcare Systems, Practice Management & Quality

2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination

3 Chapter 3: Ethics, Law, Biostatistics & Health Equity

3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism

4 Chapter 4: Lifestyle Counseling & Behavior Change

4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling

5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention

5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling

6 Chapter 6: Routine Adult Immunizations

6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise

7 Chapter 7: Pediatric Health Maintenance & Surveillance

7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride

8 Chapter 8: Behavioral Health & Safety Screening

8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling

9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic

9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening

10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic

10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling

11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate

11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making

12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception

12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C

13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care

13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam

14 Chapter 14: Emergent Cardiovascular Conditions

14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies

15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises

15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management

16 Chapter 16: Vascular & Thromboembolic Emergencies

16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion

17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness

17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion

18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies

18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies

19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies

19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice

20 Chapter 20: Acute Pulmonary & Airway Emergencies

20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction

21 Chapter 21: Acute Traumatic Injuries & Wound Care

21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites

22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies

22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises

23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies

23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection

24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies

24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis

25 Chapter 25: Hematologic, Urologic & Dental Emergencies

25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma

26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies

26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia

27 Chapter 27: Acute Head, Neck & Neurologic Symptoms

27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring

28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms

28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis

29 Chapter 29: Acute Upper Respiratory Tract Infections

29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion

30 Chapter 30: Acute Lower Respiratory Infections & Cough

30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia

31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions

31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation

32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms

32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation

33 Chapter 33: Acute Upper Gastrointestinal Conditions

33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness

34 Chapter 34: Acute Lower Gastrointestinal Conditions

34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani

35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders

35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes

36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders

36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis

37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions

37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation

38 Chapter 38: Acute Infectious Dermatoses

38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum

39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses

39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma

40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries

40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains

41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries

41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes

42 Chapter 42: Acute Ambulatory Fractures & Dislocations

42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation

43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls

43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients

44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain

44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies

45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions

45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction

46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions

46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation

47 Chapter 47: Acute Women's Health & Early Pregnancy Care

47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder

48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination

48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis

49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections

49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses

50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia

50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT

51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases

51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy

52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD

52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria

53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus

53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance

54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases

54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition

55 Chapter 55: Chronic Endocrine Disorders

55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders

56 Chapter 56: Chronic Kidney Disease & Venous Disorders

56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD

57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases

57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy

58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care

58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders

59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders

59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome

60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders

60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care

61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders

61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness

62 Chapter 62: Chronic Psychiatric Disorders

62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder

63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions

63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating

64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation

64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy

65 Chapter 65: Chronic Dermatologic Conditions

65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus

66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care

66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control

67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit

67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit

23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection

Key Takeaways Explain This Topic AI

Intramuscular Epinephrine administered into the anterolateral vastus lateralis (0.3-0.5 mg in adults; 0.01 mg/kg in pediatrics) is the undisputed first-line lifesaving medication for anaphylaxis, achieving peak plasma levels significantly faster than subcutaneous or deltoid routes.

Antihistamines (H1/H2 blockers) and systemic corticosteroids are strictly second-line adjunctive therapies that do not treat hypotension, bronchospasm, or laryngeal edema; they must NEVER be administered as monotherapy or substitute for epinephrine.

Anaphylaxis is diagnosed clinically via the NIAID/FAAN criteria: acute onset of skin/mucosal symptoms with respiratory compromise or hypotension; exposure to a likely allergen with >=2 organ systems involved; or hypotension alone following exposure to a known allergen.

Patients with anaphylaxis must be maintained strictly in a recumbent/supine position with lower extremities elevated; allowing the patient to abruptly sit up or stand can precipitate empty ventricle syndrome, acute cardiovascular collapse, and pulseless electrical activity.

Patients on chronic beta-blocker therapy who experience refractory anaphylaxis require intravenous Glucagon (1-5 mg IV over 5 minutes, followed by 5-15 mcg/min infusion), which activates myocardial and vascular adenylate cyclase through non-adrenergic pathways to bypass blocked beta receptors.

Last updated: September 2026

Anaphylaxis Pathophysiology & Classification

Anaphylaxis is an acute, life-threatening, systemic hypersensitivity reaction characterized by rapid onset of airway, breathing, or circulatory compromise, usually accompanied by cutaneous manifestations. Without prompt recognition and epinephrine administration, progression to asphyxiation or cardiovascular collapse can occur within minutes.

Immunologic IgE-Mediated Anaphylaxis (Type I Hypersensitivity)

Sensitization Phase : Initial exposure to an allergen (e.g., peanut protein, beta-lactam antibiotic, hymenoptera venom) stimulates allergen-specific T helper 2 (Th2) cells, which induce B-cell class switching to produce allergen-specific Immunoglobulin E (IgE) . Secreted IgE binds with high affinity to Fc-epsilon-RI receptors on the surface of tissue mast cells and circulating basophils.

Effector Phase (Re-Exposure) :

Re-exposure to the allergen leads to antigen cross-linking of adjacent IgE-Fc-epsilon-RI receptor complexes , triggering cellular activation and explosive exocytosis of storage granules.

Preformed Mediators (Released Immediately) :

Histamine : Stimulates H1 receptors (causing peripheral vasodilation, increased capillary permeability, pruritus, and bronchoconstriction) and H2 receptors (causing gastric acid secretion, coronary vasospasm, and chronotropic/inotropic cardiac stimulation).

Tryptase : A serine protease released exclusively by mast cells. Serum tryptase levels peak at 1 to 2 hours post-reaction and remain elevated for up to 4 to 6 hours. While not useful in acute emergency triage, an elevated serum tryptase helps retrospectively confirm anaphylaxis.

Carboxypeptidase A3 and Chymase .

Newly Synthesized Lipid Mediators (Eicosanoids) :

Leukotrienes (LTC4, LTD4, LTE4) : Formerly known as the slow-reacting substance of anaphylaxis . Exert potent bronchoconstrictor effects 1,000 times more potent than histamine and dramatically increase microvascular permeability.

Prostaglandin D2 (PGD2) : Promotes bronchospasm, peripheral vasodilation, and facial flushing.

Platelet-Activating Factor (PAF) : Causes profound peripheral vasodilation, vascular leakage, and myocardial depression; circulating PAF levels correlate directly with the clinical severity of anaphylaxis.

Non-IgE-Mediated (Non-Immunologic) Anaphylaxis

Historically referred to as anaphylactoid reactions , these episodes occur without IgE antibody cross-linking.

Mechanism : Agents directly stimulate mast cell and basophil degranulation (e.g., via the MRGPRX2 receptor) or activate the complement cascade (yielding anaphylatoxins C3a and C5a).

Common Triggers : Intravenous iodinated radiocontrast media, vancomycin ("red man syndrome"), intravenous opioids (morphine, codeine), dextrans, and extreme cold or physical exertion.

Clinical Management Rule : Non-IgE reactions are clinically indistinguishable from IgE-mediated anaphylaxis and are treated identically . Epinephrine remains the immediate first-line drug of choice.

NIAID/FAAN Clinical Diagnostic Criteria

Anaphylaxis is an urgent clinical diagnosis. Laboratory testing must never delay management. The National Institute of Allergy and Infectious Disease and Food Allergy and Anaphylaxis Network ( NIAID/FAAN ) consensus criteria outline three distinct clinical scenarios: NIAID/FAAN CLINICAL DIAGNOSTIC CRITERIA

• ┌─────────────────────────────────────────────────────────────────┐
• │ CRITERION 1: ACUTE ONSET + SKIN/MUCOSA + RESPIRATORY or BP │
• │ • Acute onset of illness (minutes to hours) with skin/mucosal │
• │ involvement (generalized hives, pruritus, flushing, angioedema)│
• │ PLUS AT LEAST ONE OF: │
• │ a) Respiratory Compromise (dyspnea, wheeze, stridor, hypoxemia)│
• │ b) Reduced BP or End-Organ Dysfunction (syncope, collapse) │
• ├─────────────────────────────────────────────────────────────────┤
• │ CRITERION 2: EXPOSURE TO LIKELY ALLERGEN + >=2 SYSTEMS │
• │ • Two or more occurring rapidly after exposure to LIKELY allergen:│
• │ a) Skin/Mucosal Tissue (hives, pruritus, lip/tongue swelling) │
• │ b) Respiratory Compromise (dyspnea, bronchospasm, stridor) │
• │ c) Reduced BP or End-Organ Dysfunction (hypotonia, syncope) │
• │ d) Persistent GI Symptoms (cramping abdominal pain, vomiting) │
• ├─────────────────────────────────────────────────────────────────┤
• │ CRITERION 3: EXPOSURE TO KNOWN ALLERGEN + REDUCED BP │
• │ • Reduced BP alone after exposure to a KNOWN allergen: │
• │ - Adults: SBP <90 mmHg or >30% decrease from baseline │
• │ - Children: Age-specific low SBP or >30% decrease │
• └─────────────────────────────────────────────────────────────────┘

The Critical Diagnostic Pitfall : Up to 10% to 20% of patients with severe anaphylaxis have NO cutaneous signs (no hives, erythema, or angioedema). In rapidly evolving, severe reactions—particularly from intravenous drugs or insect venom—cardiovascular collapse (Criterion 3) or isolated asphyxia can occur before skin manifestations have time to develop. Clinicians must not rule out anaphylaxis simply because the skin is clear!

First-Line Pharmacotherapy: Intramuscular Epinephrine

Intramuscular epinephrine is the primary, first-line, lifesaving medication of choice. There are absolute zero contraindications to epinephrine in a patient experiencing life-threatening anaphylaxis .

Pharmacodynamic Actions Across Adrenergic Receptors

Alpha-1 Adrenergic Agonism :

• Induces potent vasoconstriction in peripheral vascular beds;
• Reverses profound peripheral vasodilation and distributive shock;
• Decreases post-capillary venular leakage, directly reducing laryngeal edema and macroglossia;

Elevates systemic vascular resistance and raises blood pressure.

Beta-1 Adrenergic Agonism :

Increases myocardial contractility (positive inotropy) and heart rate (positive chronotropy), augmenting cardiac output to reverse circulatory collapse.

Beta-2 Adrenergic Agonism :

Promotes rapid bronchial smooth muscle relaxation, reversing bronchospasm;

Crucial Cellular Downregulation : Beta-2 receptor activation on mast cells and basophils stimulates adenylate cyclase, elevating intracellular cyclic adenosine monophosphate ( cAMP ). High intracellular cAMP directly inhibits further exocytosis of mast cell and basophil storage granules , shutting down the inflammatory mediator cascade at its cellular source.

Dosing and Administration Protocol

Adult Dosing : 0.3 mg to 0.5 mg IM (0.3 to 0.5 mL of 1:1,000 [1 mg/mL] concentration).

Pediatric Dosing : 0.01 mg/kg IM of 1:1,000 concentration (maximum single dose: 0.3 mg).

Autoinjector Weight Tiers : 0.15 mg autoinjector for children weighing 10 kg to 25 kg; 0.3 mg autoinjector for individuals weighing >25 kg.

Anatomical Route of Administration : Anterolateral middle third of the thigh (Vastus Lateralis muscle) .

Pharmacokinetic Superiority : Landmark pharmacokinetic studies demonstrated that intramuscular injection into the vastus lateralis achieves a peak plasma concentration (Cmax) significantly faster (mean time to peak ~8 minutes) and up to 10-fold higher compared to subcutaneous administration or intramuscular injection into the deltoid muscle. Subcutaneous administration causes local alpha-1 vasoconstriction, trapping the drug locally and severely delaying systemic absorption.

Repeat Dosing : Can be repeated every 5 to 15 minutes as clinically indicated for persistent, refractory, or progressive symptoms. Approximately 10% to 20% of patients require a second dose. EPINEPHRINE ROUTE PHARMACOKINETICS

• Vastus Lateralis IM: Peak Cmax achieved in ~8 minutes (HIGHEST & FASTEST)
• Deltoid IM: Peak Cmax achieved in ~34 minutes (Delayed)
• Subcutaneous (SQ): Peak Cmax achieved in ~45 minutes (Slowest; local vasoconstriction)
• Intravenous Epinephrine Warning

Intravenous Epinephrine Boluses (1:1,000) are LETHAL : Rapid IV push of concentrated 1:1,000 epinephrine causes severe hypertensive crises, intracranial hemorrhage, ventricular fibrillation, and myocardial infarction.

IV Epinephrine is Reserved Strictly for Refractory Shock or Cardiac Arrest : Administer only under continuous telemetry monitoring via a dedicated infusion pump, diluted as an infusion (0.1 mcg/kg/min or 1 to 10 mcg/min) or using dilute 1:10,000 (0.1 mg/mL) or 1:100,000 push-dose formulations.

Biphasic Anaphylaxis & Post-Stabilization Monitoring

Definition : The recurrence of systemic anaphylactic symptoms after complete resolution of the initial acute episode, occurring without any re-exposure to the inciting allergen .

Incidence & Timing : Biphasic reactions develop in 10% to 20% of anaphylaxis cases. While they characteristically emerge within 4 to 12 hours after the initial reaction, onset has been documented up to 72 hours later.

Risk Factors for Biphasic Reactions :

• Severe initial clinical presentation (e.g., severe hypotension, respiratory arrest, wide pulse pressure);
• Delayed epinephrine administration (>30 to 60 minutes from symptom onset);
• Requirement for more than one dose of epinephrine to achieve initial stabilization;

Ingestion of large allergen loads (e.g., oral food allergen).

Mandatory Clinical Observation Period :

All patients with anaphylaxis must be observed in a medical facility for a minimum of 4 to 8 hours following complete resolution of symptoms.

Patients with risk factors for biphasic reactions (severe hypotension, requirement for multiple epinephrine doses, or underlying severe asthma) warrant prolonged observation or overnight hospital admission (12 to 24 hours) .

Discharge Care Bundle :

• Prescribe two epinephrine autoinjectors (never a single pen);
• Provide hands-on patient education on self-administration into the outer thigh;
• Provide a written Anaphylaxis Emergency Action Plan;

Recommend medical alert identification and arrange formal referral to an allergist/immunologist.

Secondary Adjunctive Therapies: What the Board Tests

[!CRITICAL] CRITICAL BOARD PEARL : Antihistamines and corticosteroids are strictly SECOND-LINE adjunctive agents . They do NOT treat or prevent laryngeal edema, bronchospasm, or distributive shock. They have a slow onset of action and must NEVER be used as monotherapy or substitute for epinephrine !

Medication Class Agent & Route Clinical Indication Limitations & Pearls

H1 Antihistamine Diphenhydramine 25 – 50 mg IV / PO Treats cutaneous pruritus, flushing, and urticaria Does NOT reverse airway edema or shock; causes sedation that obscures mental status changes

H2 Antihistamine Famotidine 20 mg IV / PO Blocks cardiac and vascular H2 receptors; provides synergistic cutaneous relief with H1 blockers Adjunctive only; does not reverse hypotension or bronchospasm

Systemic Corticosteroid Methylprednisolone 1 – 2 mg/kg IV OR Prednisone 50 mg PO Blunts late-phase inflammation; onset takes 4 to 6 hours Recent systematic reviews prove corticosteroids do NOT reliably prevent biphasic reactions! Never use as initial rescue

Inhaled Beta-2 Agonist Albuterol 2.5 – 5.0 mg nebulized Relieves persistent lower airway bronchospasm / wheezing refractory to epinephrine Does NOT treat upper airway laryngeal edema or subglottic swelling

Isotonic Crystalloids Balanced Crystalloids 1 – 2 Liters IV bolus (20 mL/kg pediatrics) Rapid restoration of intravascular volume in distributive shock Massive capillary leak can sequester up to 35% of intravascular volume into extravascular spaces within 10 minutes

Refractory Anaphylaxis in Patients Taking Beta-Blockers

Patients maintained on chronic beta-adrenergic antagonist therapy (e.g., metoprolol, propranolol, atenolol, carvedilol) represent a high-risk population prone to catastrophic, treatment-refractory anaphylaxis.

The Pathophysiological Dilemma

Beta-blockers saturate and antagonize beta-1 and beta-2 adrenergic receptors.

When standard doses of epinephrine are administered, the drug cannot activate blocked beta-2 receptors (failing to induce bronchodilation or halt mast cell mediator release) or beta-1 receptors (failing to restore cardiac contractility).

Simultaneously, exogenous epinephrine stimulates unblocked alpha-1 receptors , which can trigger severe unopposed peripheral vasoconstriction , leading to severe paradoxical hypertension, profound reflex bradycardia, coronary spasm, or refractory distributive collapse.

The Specific Treatment of Choice: Intravenous Glucagon

Pharmacologic Mechanism : Glucagon binds to specific, non-adrenergic glucagon G-protein coupled receptors on cardiac myocytes and vascular smooth muscle cells. This directly stimulates adenylate cyclase, converting ATP to intracellular cAMP , completely bypassing blocked beta-adrenergic receptors. Elevated cAMP restores positive inotropy and chronotropy and promotes smooth muscle relaxation.

Dosing Protocol :

Initial Bolus : 1 mg to 5 mg IV administered slowly over 5 minutes ;

Maintenance Infusion : Followed by a continuous infusion of 5 to 15 mcg/min , titrated to clinical hemodynamics and resolution of bronchospasm.

Side Effect : Glucagon causes a high incidence of severe nausea and vomiting . Because the patient may have an unprotected airway, position the patient in the lateral recumbent position to prevent aspiration.

Emergency Airway Protection & Patient Positioning PATIENT POSITIONING WARNING

• STRICTLY RECUMBENT / SUPINE WITH LEGS ELEVATED
• ┌─────────────────────┐
• Head │ Torso │ Legs Elevated (30-45°)
• O─────────────┴─────────────────────┴────────────/

NEVER ALLOW AN ANAPHYLACTIC PATIENT TO STAND OR SIT UP ABRUPTLY!

• Sudden standing -> Venous pooling in dilated splanchnic & lower limbs
• > Zero venous return -> "EMPTY VENTRICLE SYNDROME"

-> Sudden Pulseless Electrical Activity (PEA) & Death within seconds!

1. Patient Positioning and "Empty Ventricle Syndrome"

Patients experiencing anaphylaxis must be maintained strictly in a recumbent or supine position with lower extremities elevated , unless severe dyspnea dictates reclining in a semi-Fowler position (and even then, never allow them to stand).

The Fatal Mechanism : Massive histamine- and PAF-mediated vasodilation creates an enormous, low-resistance vascular capacitance bed. If the patient abruptly sits up or stands, gravity immediately causes venous blood to pool in the lower extremities and splanchnic circulation.

Venous return to the right heart abruptly drops to zero, depriving the left ventricle of preload ( "empty ventricle syndrome" ). The heart pumps against empty chambers, precipitating sudden pulseless electrical activity (PEA) and cardiac arrest within seconds .

2. Early Airway Protection & Intubation

Progressive laryngeal edema, epiglottic swelling, and tongue enlargement can completely obliterate the glottic aperture in minutes.

Indications for Immediate Intubation : Stridor, hoarseness, dysphonia ("hot potato voice"), tongue/pharyngeal swelling, or persistent severe hypoxemia despite epinephrine.

Intubation Strategy :

Intubate early : Attempting intubation late through distorted, edematous pharyngeal tissues is technically hazardous.

Have video laryngoscopy ready, select an endotracheal tube 0.5 to 1.0 mm smaller than normal (e.g., 6.0 or 6.5 mm cuffed ETT) to negotiate the narrowed glottis, utilize an endotracheal tube introducer (bougie), and have a surgical cricothyrotomy kit open and immediately available at the bedside .

Loading diagram... Emergency Anaphylaxis Management and Refractory Algorithm